Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells

Journal of Andrology

Volumn 29, Issue 6, 2008, Pages 661-668

  Tsui, Ke Hung ^a   Feng, Tsui Hsia ^b   Lin, Chang Mei ^b   Chang, Phei Lang ^a   Juang, Horng Heng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Androgen receptor; IL 6; PDEF; PSA; R1881

Indexed keywords

ANDROGEN; BLOCKING ANTIBODY; CURCUMIN; INTERLEUKIN 6; METRIBOLONE; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; QUALITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT;

ANDROGENS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-6; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 56249138279     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.108.004911     Document Type: Article

References (30)

1. Ahmedin J, Rebecca S, Elizabeth W, Taylor M, Jiaquan X, Carol S, Michael JT. Cancer statistics. Calif Cancer J Clin. 2006;56:106-130.
2. Bemis DL, Katz AE, Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs. 2006;15:1191-1200.
3. Chen CD, Sawyers CL. NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol. 2002;22:2862-2870.
4. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 2000;60:2132-2135.
5. Chen Y-R, Tan T-H. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene. 1998;17:173-178.
6. Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky SA, Gautam SC. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Therap. 2004;3:803-812.
7. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. 2001;47:293-303.
8. Dorai T, Dutche JP, Dempster DW, Wiernik PH. Therapeutic potential of curcumin in prostate cancer - V: interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate. 2004;60:1-17.
9. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol. 2000;4:1-6.
10. Edwards J, Bartlett JMS. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int. 2005;95:1327-1335.
11. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998;58:4640-4645.
12. Hong JH, Ahn KS, Bae E, Jeon SS, Choi HY. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis. 2006;9:147-152.
13. Hsieh M-L, Juang HH. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J Androl. 2005;26:422-428.
14. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA. Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res. 2004;64:2619-2626.
15. Juang HH, Hsieh M-L, Tsui KH. Testosterone modulates mitochondrial aconitase in the full-length human androgen receptor-transfected PC-3 prostatic carcinoma cells. J Mol Endocrinol. 2004;33:121-132.
16. Khor TO, Keum YS, Lin W, Kim JH, Hu R, Shen G, Xu C, Gopalakrishnan A, Reddy B. Zheng X, Conney AH, Kong AN. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res. 2006;66:613-621.
17. Kim JH, Xu C, Keum YS, Reddy B, Conney A, Kong AT. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis. 2006;27:475-482.
18. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res. 2001;7:1773-1781.
19. Lin L, Shi Q, Nyarko AK, Bastow KF, Wu CC, Su CY, Shih CC, Lee KH. Antitumor agents 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem. 2006;49:3963-3972.
20. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 2001;20:7597-7609.
21. Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S, Rhim JS. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol. 2002;21:825-830.
22. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, Endress G, Kunsch C, Libermann TA. PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem. 2000;275:1216-1225.
23. Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang HK, Itokawa H, Su CY, Shih C, Chiang T, Chang E, Lee Y, Tsai MY, Chang C, Lee KH. Antitumor agents 217, curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem. 2002;45:5037-5042.
24. Thelen P, Jarryu H, Ringert RH, Wuttke W. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cell. Planta Med. 2004;70:397-400.
25. Thelen P, Scharf JG, Burfeind P, Hemmerlein B, Wuttke W, Spengler B, Christoffel V, Ringert RH, Seidlova-Wuttke D. Tectorigenin and other phytochemical extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer. Carcinogenesis. 2005;26:1360-1367.
26. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ. Dietary polyphenolic phytochemicals - promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer. 2007;120:451-458.
27. Tsui KH, Chang PL, Juang HH. Zinc blocks gene expression of mitochondrial aconitase in human prostatic carcinoma cells. Int J Cancer. 2006;118:609-615.
28. Tsui KH, Chang PL, Lin HT, Juang HH. Down-regualtion of the prostate specific antigen promoter by p53 in human prostate cancer cells. J Urol. 2004a;172:2035-2039.
29. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate. 2008;68:610-619.
30. Tsui KH, Wu L, Chang PL, Hsieh ML, Juang HH. Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes. J Urol. 2004b;172:2029-2034.